• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CMB

CAMBIUM BIO LIMITED

20.8% ! 32.0¢
Market Cap $5.850M  !

Cambium Bio Limited, formerly Regeneus Ltd, is an Australia-based clinical-stage... Cambium Bio Limited, formerly Regeneus Ltd, is an Australia-based clinical-stage regenerative medicine company focusing on the development of biologics for ophthalmology and tissue repair applications. Its technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Its lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. Elate Ocular is formulated from the processing of base human platelets sourced not from patients, but generally healthier younger eligible donors at U.S. blood collection centers. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. It also manufactures and sells stem cell growth supplements, such as UltraGRO Advanced, UltraGRO Pure (xeno-free), and UltraGRO Pure GI (xeno-free, gamma irradiated).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
CMB 12/07/25 2 942
12/07/25 Last post  xerxer Comments Created with Sketch.  2  Views Created with Sketch.  942 
CMB 30/06/25 0 218
30/06/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  218 
CMB 13/06/25 2 1.2K
TRENDING NEWS

The final ingredient SS1 needs in our "recipe for an 8,000% VUL style price run"... but ingredient #6 is the hardest one to get...

NEWS
28 Jul 2025
13/06/25 Last post  nigelnz Comments Created with Sketch.  2  Views Created with Sketch.  1.2K 
CMB 23/05/25 0 226
23/05/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  226 
CMB 22/05/25 0 231
22/05/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  231 
CMB 22/05/25 0 214
22/05/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  214 
CMB 21/05/25 0 249
21/05/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  249 
CMB 15/04/25 6 3.6K
15/04/25 Last post  xerxer Comments Created with Sketch.  6  Views Created with Sketch.  3.6K 

See All Discussions arrow Created with Sketch.

Timeline

Cambium Bio Clears FDA Regulatory Hurdles
11 Jul 09:10
 
Cambium Bio Receives Ethics Approvals
30 Jun 09:23
 
Change of Address
23 May 15:56
 
Initial Director's Interest Notice - Denese Marks
22 May 16:36
 
Final Director's Interest Notice - Barry Sechos
22 May 16:35
 
Board and Company Secretary Changes
21 May 12:32
 
View More arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
32.0¢
Change
0.055(20.8%)
Mkt cap ! $5.850M
Open High Low Value Volume
28.5¢ 32.0¢ 28.5¢ $14.12K 47.96K

Buyers (Bids)

No. Vol. Price($)
1 56261 29.0¢
 

Sellers (Offers)

Price($) Vol. No.
32.0¢ 3987 2
View Market Depth
Last trade - 15.33pm 28/07/2025 (20 minute delay) ?
CMB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.